Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells'. Together they form a unique fingerprint.

Chemical Compounds